Drew Moghanaki/LinkedIn
Apr 26, 2025, 19:46
Drew Moghanaki: I’m surprised that more radiation oncologists and medical physicists aren’t discussing this issue
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the David Geffen School of Medicine at UCLA, shared on LinkedIn:
“I’m surprised that more radiation oncologists and medical physicists aren’t discussing this issue. At UCLA, we’ve long recognized the fundamental limitations of 4DCT – limitations that may be contributing to higher-than-expected treatment failures after lung SBRT. That’s why our team transitioned to 5DCT in 2019, leading to extraordinary tumor control rates over 98%.
It’s time we started a broader conversation about the accuracy of today’s commercially available tumor motion management systems and how to get 5DCT into the hands of clinics worldwide.”
4DCT is long overdue for improvement
Authors: Erik Tryggestad et al.
See this impactful insight related to SBRT on OncoDaily:
New Paper Alert: SMART ONE Trial: Single Fraction MR-Guided SBRT for Visceral Tumors
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 26, 2025, 19:27
Apr 26, 2025, 18:44
Apr 26, 2025, 18:35
Apr 26, 2025, 17:45
Apr 26, 2025, 17:34